• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/6/25 8:05:31 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PULM alert in real time by email
    false 0001574235 0001574235 2025-08-06 2025-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 6, 2025

     

    PULMATRIX, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36199   46-1821392

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    945 Concord Street, Suite 1217

    Framingham, MA 01701

    (Address of principal executive offices) (Zip Code)

     

    (888) 355-4440

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On August 6, 2025, Pulmatrix, Inc. issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

     

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, being furnished pursuant to Item 2.02, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    99.1   Press Release dated August 6, 2025*
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

    * This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.”

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PULMATRIX, INC.
         
    Date: August 6, 2025 By: /s/ Peter Ludlum
        Peter Ludlum
        Interim Chief Executive Officer and Interim Chief Financial Officer

     

     

     

    Get the next $PULM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PULM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PULM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Batycky Richard P.

    4 - Pulmatrix, Inc. (0001574235) (Issuer)

    1/30/23 4:05:40 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Varadan Anand

    4 - Pulmatrix, Inc. (0001574235) (Issuer)

    1/30/23 4:05:42 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Cabell Christopher

    4 - Pulmatrix, Inc. (0001574235) (Issuer)

    1/30/23 4:05:43 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PULM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

    Proposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small or large molecule drugs to the lungs by inhalation FRAMINGHAM, Mass., Aug, 6, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced second quarter financial results for 2025 and provided a

    8/6/25 8:05:00 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

    Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced

    5/15/25 8:05:00 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

    Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financi

    3/21/25 8:05:00 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PULM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Pulmatrix with a new price target

    HC Wainwright & Co. reiterated coverage of Pulmatrix with a rating of Buy and set a new price target of $5.00 from $10.00 previously

    4/13/21 6:23:02 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PULM
    SEC Filings

    View All

    SEC Form 10-Q filed by Pulmatrix Inc.

    10-Q - Pulmatrix, Inc. (0001574235) (Filer)

    8/6/25 8:20:44 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Pulmatrix, Inc. (0001574235) (Filer)

    8/6/25 8:05:31 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Pulmatrix Inc.

    425 - Pulmatrix, Inc. (0001574235) (Subject)

    6/16/25 4:17:07 PM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PULM
    Leadership Updates

    Live Leadership Updates

    View All

    Pulmatrix appoints Director Anand Varadan

    LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

    7/27/21 10:00:00 AM ET
    $PULM
    $CHMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $PULM
    Financials

    Live finance-specific insights

    View All

    Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

    PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass., March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.

    3/30/23 9:05:00 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PULM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

    SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

    1/2/24 9:42:57 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

    SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

    2/8/23 6:08:04 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pulmatrix Inc. (Amendment)

    SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)

    1/10/23 11:21:19 AM ET
    $PULM
    Biotechnology: Pharmaceutical Preparations
    Health Care